Advocacy Chats
Educational Conversations on Policy Issues & Cancer Research
How 340B in Big Health Systems is Hurting Patients
The 340B Drug Pricing Program is meant to provide access to prescription drugs at significantly discounted prices to patients in need—but the program’s current structure allows hospitals to keep cost savings instead of passing them on to patients who need them most. Join COA’s Director of Patient Advocacy & Education Rose Gerber, Executive Director Ted Okon, and Managing Director Nicolas Ferreyros on October 12, 2022, at 12 p.m. ET, to discuss the history of the 340B Program, how it got to its current state, the latest data on use of the program, and how it can be fixed so its results match its intentions.